CVS announces it will close around 900 stores; states in the upper Midwest are suffering another COVID-19 surge; Biden increases federal waterway protection.
CVS announced it will close around 300 stores per year over the next 3 years, The New York Times reports. The move comes as the retail pharmacy plans to focus more on offering health care services and expanding digital services. Currently, around 70% of the pharmacy’s customers are enrolled in its text messaging service. Overall, the closures will affect about 9% of the company’s more than 9900 brick and mortar stores. The transition will begin in spring 2022 but is not expected to affect pharmacies within Target stores.
Average daily cases of COVID-19 have spiked by 35% in recent weeks, CDC data show, with the upper Midwest seeing the largest surge in infections, according to CBS News. One critical care physician in Minneapolis, Minnesota, said he had never seen so many people on a ventilator at once and that his intensive care unit is full. The majority of patients with COVID-19 in the hospital are unvaccinated. In the last week alone in Minnesota, COVID-19 cases rose 47% and hospital admissions rose 24%. The largest increase was seen among those aged 30 to 49 years.
President Joe Biden has acted to restore federal protections for hundreds of thousands of small streams, wetlands, and other waterways in an effort to safeguard clean water, ABC News reports. The action, announced by the Environmental Protection Agency and the Army, reinstates a rule that was put in place before 2015, prior to a Trump-era rollback that reduced the number of federally protected waterways by about 25%. In June, the administration signaled it would issue new regulations defining which waterways are protected by the Clean Water Act; in August, an Arizona judge threw out the Trump water rule.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
For Neuromuscular Disease Community, an Era of Opportunities and Threats
March 17th 2025Robert Califf, MD, former commissioner of the FDA, delivered a keynote address at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference that highlighted the enormous opportunities for progress in neuromuscular disease care amid a changing policy environment.
Read More
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More
Oz Confirmation Hearing Probes Vision for Medicaid but Coalesces Around Well-Being
March 14th 2025Mehmet Oz, MD, the nominee to lead CMS under the Trump administration, testified in a confirmation hearing before the Senate Finance Committee, where he found common ground on improving outcomes through healthier lifestyle choices but encountered repeated questions on potential Medicaid cuts.
Read More